Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6064608 | 0.91 | CCKBR (0.54) | CCKBREPHX2 | |
| SCHEMBL6065140 | 0.91 | CCKBR (0.54) | CCKBREPHX2 | |
| SCHEMBL6065559 | 0.91 | CCKBR (0.54) | CCKBREPHX2 | |
| SCHEMBL6065051 | 0.91 | CCKBR (0.54) | CCKBR | |
| SCHEMBL6065050 | 0.90 | CCKBR (0.53) | CCKBREPHX2 | |
| SCHEMBL6065521 | 0.90 | CCKBR (0.55) | CCKBREPHX2 | |
| SCHEMBL6065151 | 0.90 | CCKBR (0.57) | CCKBREPHX2 | |
| SCHEMBL6065185 | 0.90 | CCKBR (0.53) | CCKBREPHX2 | |
| SCHEMBL6065177 | 0.90 | CCKBR (0.53) | CCKBR | |
| SCHEMBL6065045 | 0.89 | CCKBR (0.52) | CCKBREPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105558-B2 | Gastrin and cholecystokinin receptor lignads (iv) | THE JAMES BLACK FOUNDATION LIMITED (GB) | 2006-09-12 | — | — | US | disclosed |
| US-20030195237-A1 | Gastrin and cholecystokinin receptor lignads (iv) | JAMES BLACK FOUNDATION LIMITED (GB) | 2003-10-16 | — | — | US | disclosed |
| WO-2001085704-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS (IV) | JAMES BLACK FOUNDATION LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195237-A1 | Gastrin and cholecystokinin receptor lignads (iv) | CCKAR, CCKBR, GRPR | CCKBR 2/4885EPHX2 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.